Abstract | OBJECTIVE: CASE SUMMARY: A male neonate, born at 37 weeks' gestation, presented with a goiter without other signs of hypothyroidism. His serum thyroid-stimulating hormone concentration was high and unbound tetrathyroxine concentration was low, indicating that chronic exposure to lithium was present. Oral thyroxine treatment was initiated when the infant was 3 days old and continued for 11 weeks. Treatment was effective in reducing the goiter and hormone concentrations, and allowing normal growth and psychomotor development during the following 3.5 months. Other drugs taken by the mother during pregnancy are not known to induce thyroid abnormalities. DISCUSSION: CONCLUSIONS:
Lithium is a well-known goitrogenic agent. Thus, if lithium treatment needs to be continued during pregnancy in women with bipolar disorder, adequate screening for morphology by ultrasonography and systematic hormonal biological control in newborns are recommended.
|
Authors | Florence Frassetto, Florence Tourneur Martel, Claude-Elisabeth Barjhoux, Céline Villier, Brigitte Le Bot, Françoise Vincent |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 36
Issue 11
Pg. 1745-8
(Nov 2002)
ISSN: 1060-0280 [Print] United States |
PMID | 12398572
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Thyrotropin
- Lithium
- Thyroxine
|
Topics |
- Bipolar Disorder
(drug therapy)
- Female
- Goiter
(blood, chemically induced, drug therapy)
- Humans
- Hypothyroidism
(chemically induced, drug therapy)
- Infant, Newborn
- Lithium
(adverse effects)
- Male
- Maternal-Fetal Exchange
- Pregnancy
- Thyrotropin
(blood)
- Thyroxine
(therapeutic use)
|